Physician profile
Chad Aaron Shultz
NPI 1003909094
$1,294.90
in general payments reported to CMS, 2019-2025
14 companies · $527 in 2025
The $527 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.44 · 2020: $13.99 · 2021: $132 · 2022: $245 · 2023: $203 · 2024: $115 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $454.00 | 2019-2025 | Precision7, Clareon, Tryptyr |
| Abbvie INC. | $312.61 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Johnson & Johnson Surgical Vision, INC. | $103.66 | 2025 | Veritas Vision System |
| Kala Pharmaceuticals, INC. | $69.38 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $67.90 | 2023-2025 | Infuse |
| Oyster Point Pharma, INC. | $53.70 | 2022-2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $43.30 | 2021 | |
| Coopervision INC. | $37.38 | 2025 | Biofinity Contact Lens, Myday Contact Lens |
| Allergan, INC. | $36.38 | 2021-2022 | |
| Harrow Eye, LLC | $36.13 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $36.09 | 2024 | Xdemvy |
| Shire North American Group INC | $16.37 | 2019 | |
| Dompe US, INC. | $14.82 | 2021 | |
| Aerie Pharmaceuticals, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Shultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.